Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Poolbeg Pharma Ltd. ( (GB:POLB) ) has shared an update.
Poolbeg Pharma announced its participation in key industry conferences in March and April 2025, including the Master Investor Show, BioTrinity, and the LSX World Congress. These events will provide a platform for Poolbeg to showcase its drug candidate POLB 001, an oral preventative therapy for cancer immunotherapy-induced CRS, and engage in discussions on building resilience in life sciences, potentially enhancing its industry positioning and stakeholder engagement.
More about Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focused on developing innovative medicines to address unmet medical needs, with a strong and growing portfolio of development assets.
YTD Price Performance: -61.27%
Average Trading Volume: 2,317,689
Technical Sentiment Signal: Buy
For an in-depth examination of POLB stock, go to TipRanks’ Stock Analysis page.